The current state of surgery for pancreatic cancer

K. E. Poruk, Matthew J Weiss

Research output: Contribution to journalReview article

Abstract

Pancreatic adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality in the United States, with a dismal 5-year survival of only 6% for all stages. Surgical resection offers the best opportunity for prolonged survival at this time, but is limited to patients with locally resectable tumors and no distant metastases. Although only 10-20% of patients present with early stage disease are amenable to surgical resection, remarkable advancements have been made over the past several decades leading to improved morbidity and mortality after pancreatic resection. This article will review the current state of pancreatic surgery including its role in the multidisciplinary approach to pancreatic cancer treatment, advances and controversies in surgical technique, and the limitations of surgical therapy that will need to be addressed in the future to improve survival for patients with pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)101-115
Number of pages15
JournalMinerva Gastroenterologica e Dietologica
Volume61
Issue number2
StatePublished - Jun 1 2015

Fingerprint

Pancreatic Neoplasms
Survival
Mortality
Neoplasms
Adenocarcinoma
Neoplasm Metastasis
Morbidity
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Gastroenterology

Cite this

The current state of surgery for pancreatic cancer. / Poruk, K. E.; Weiss, Matthew J.

In: Minerva Gastroenterologica e Dietologica, Vol. 61, No. 2, 01.06.2015, p. 101-115.

Research output: Contribution to journalReview article

Poruk, KE & Weiss, MJ 2015, 'The current state of surgery for pancreatic cancer', Minerva Gastroenterologica e Dietologica, vol. 61, no. 2, pp. 101-115.
Poruk, K. E. ; Weiss, Matthew J. / The current state of surgery for pancreatic cancer. In: Minerva Gastroenterologica e Dietologica. 2015 ; Vol. 61, No. 2. pp. 101-115.
@article{7f213dd340b14dce85d592380920e10c,
title = "The current state of surgery for pancreatic cancer",
abstract = "Pancreatic adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality in the United States, with a dismal 5-year survival of only 6{\%} for all stages. Surgical resection offers the best opportunity for prolonged survival at this time, but is limited to patients with locally resectable tumors and no distant metastases. Although only 10-20{\%} of patients present with early stage disease are amenable to surgical resection, remarkable advancements have been made over the past several decades leading to improved morbidity and mortality after pancreatic resection. This article will review the current state of pancreatic surgery including its role in the multidisciplinary approach to pancreatic cancer treatment, advances and controversies in surgical technique, and the limitations of surgical therapy that will need to be addressed in the future to improve survival for patients with pancreatic cancer.",
author = "Poruk, {K. E.} and Weiss, {Matthew J}",
year = "2015",
month = "6",
day = "1",
language = "English (US)",
volume = "61",
pages = "101--115",
journal = "Minerva Gastroenterologica",
issn = "1121-421X",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - The current state of surgery for pancreatic cancer

AU - Poruk, K. E.

AU - Weiss, Matthew J

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Pancreatic adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality in the United States, with a dismal 5-year survival of only 6% for all stages. Surgical resection offers the best opportunity for prolonged survival at this time, but is limited to patients with locally resectable tumors and no distant metastases. Although only 10-20% of patients present with early stage disease are amenable to surgical resection, remarkable advancements have been made over the past several decades leading to improved morbidity and mortality after pancreatic resection. This article will review the current state of pancreatic surgery including its role in the multidisciplinary approach to pancreatic cancer treatment, advances and controversies in surgical technique, and the limitations of surgical therapy that will need to be addressed in the future to improve survival for patients with pancreatic cancer.

AB - Pancreatic adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality in the United States, with a dismal 5-year survival of only 6% for all stages. Surgical resection offers the best opportunity for prolonged survival at this time, but is limited to patients with locally resectable tumors and no distant metastases. Although only 10-20% of patients present with early stage disease are amenable to surgical resection, remarkable advancements have been made over the past several decades leading to improved morbidity and mortality after pancreatic resection. This article will review the current state of pancreatic surgery including its role in the multidisciplinary approach to pancreatic cancer treatment, advances and controversies in surgical technique, and the limitations of surgical therapy that will need to be addressed in the future to improve survival for patients with pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=85003053965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003053965&partnerID=8YFLogxK

M3 - Review article

C2 - 25651834

AN - SCOPUS:85003053965

VL - 61

SP - 101

EP - 115

JO - Minerva Gastroenterologica

JF - Minerva Gastroenterologica

SN - 1121-421X

IS - 2

ER -